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Abstract-The &adrenergic transmembrane signal transduction was investigated in malignant B-cells 
from 15 patients with low grade non-Hodgkin’s lymphoma as compared with normal lymphocytes of 
seven healthy adults. The number of &-adrenoceptors and the response of adenylate cyclase (AC) to 
isoproterenol were slightly decreased in lymphoma cells. The responsiveness of AC to forskolin was S- 
fold lower in lymphoma cells, whereas the response to cholera toxin showed no difference. These 
findings demonstrate an impairment of the P,-adrenergic signal transduction in low grade lymphoma 
cells that particularly affects the function of AC. The comparison with forskolin resistant mutants of 
an adrenocortical tumor cell line, Yl (Schimmer er al., I Bioi @en? 262: 15521-15526, 1987), suggests 
that the availability of functional active alpha subunits of stimulatory G proteins (G,) might be reduced 
in human B-cell lymphoma, although other mechanisms known to inhibit the AC activity might be 
involved. 
Normal human lymphocytes bear &-adrenergic 
binding sites [l], whose interaction with cat- 
echolamines results in the stimulation of the enzyme 
adenylate cyclase (ACQ) via the stimulating GTP 
binding protein (G,) [2], thereby increasing the 
intracellular concentration of cyclic 3’ : 5’-adenosine 
monophosphate (CAMP). This second messenger 
seems to inhibit most functions of mature human 
lymphocytes includi~lg mitogen-induced DNA syn- 
thesis [3,4], anaerobic glycolysis [S], production of 
lymphokines [6] and antibodies 171, T-cell mediated 
cytolysis [8-IO] and motility of T- and B-cells 1111. 
However, CAMP has been found to enhance the 
differentiation of both immature lymphocytes [12] 
and lymphoma cells [13]. The plasma, urine and 
intracellular CAMP levels were reported to be 
decreased in patients with acute (ALL) and 
chronic lymphocytic leukemia (CLL) [14-171. Both 
adrenergic binding sites and the stimulation of AC 
by catecholamines were shown to be reduced in CLL 
lymphocytes [l&21]. Recently, the adenylate cyclase 
system has received increasing attention because of 
its possible role in malignant transformation 122-291 
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CAMP was demonstrated to suppress neoplastic B- 
cell proliferation in human and murine lymphoma 
cell lines [30,31]. We therefore conducted a study 
to determine the number and affinity of & 
adrenoceptors on normal and malignant human 
lymphocytes and to investigate the function of the 
&adrenergic signal transduction (receptor, G,, AC) 
in these cells by stimulation with different agents 
(isoproterenol, cholera toxin and forskolin). 
MATERIALS AND METHODS 
Patients. Fifteen patients with leukemic low grade 
non-Hodgkin lymphoma (lymphocyte count 
> 10’ cells/pL) aged from 48 to 79 years (median 68 
years; mean f SD 63.5 L 10.5 years; seven female 
eight male) treated in the Medizinische Klinik, 
Klinikum Innenstadt, Munich, Germany, entered 
the study. Six apparently healthy subjects and one 
patient with coronary heart disease without further 
complications or treatment, aged from 24 to 78 years 
(median 33; mean 2 SD 42.8 2 20.7; two female, 5 
male) served as controls. The histopathological 
entities according to the Kiel classification [32] were 
distributed as follows: 12 CLL, two immunocytoma 
(IC) and one centrocytic-centroblastic lymphoma 
(cccb). Immunophenotyping of mononucIear leu- 
cocytes (MNL) in patients showed that all were B- 
cell lymphoma, and that more than 90% of MNL 
were B-cells. CLL and IC patients were staged 
according to the Binet classification [33], the cccb 
patient according to the Ann Arbor classification 
[34]. Three of the 14 CLL and IC patients were in 
Binet stage A, six in stage B and five in stage C. 
The cccb patient was in stage IV. No patient 
received chemotherapy or took sympatholytic or 
sympathomimetic drugs. 
~u~e~~~~~. Hepes buffered Hank’s salt solution 
(HH) consisted of the following compounds diluted 
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in distilled water: 1.26 mmol/L CaC&, 5.4 mmol/L 
KCI, 0.44 mmol/L KH2P04, 0.8 mmol/L MgSO,, 
136.9 mmol/L NaCl, 0.42 mmol/L Na2HPOJ (all 
salts purchased in analytical purity from Merck. 
Darmstadt, Germany). and 25.0 mmol/L Hepes 
(Sigma Chemical Co., St Louis, MO, U.S.A.). This 
buffer was adjusted to pH 7.4 with 1 N NaOH 
solution. Forskolin, cholera toxin (vials of 1 mg 
lyophilized protein), 3-isobutyl-l-methylxanthine 
(IBMX) and (-)isoproterenol bitartrate were 
purchased from Sigma, (-)‘?odo-cyanopindolol 
(‘?IICYP; 2000 pCi/mmol) from Amersham 
(Braunschweig, Germany), and heparin from Novo 
Industrie (Mainz. Germany). (-)Timolol maleate 
was a generous gift from Merck Sharp and Dohme 
(Munich. Germany). 
Binding assny. The experimental procedure was 
performed as described previously [35]. with 
small modifications. Briefly, samples of 15-20 mL 
heparinized, venous blood were obtained between 
9 and 10 a.m. MNL were harvested by density 
gradient centrifugation [36]. The MNL fraction was 
washed twice in HH pH 7.4 and then resuspended 
in this buffer. Intact cells (5 x 10’) were incubated 
in 100 PL with varying concentrations (1.0-180 pmol/ 
L) of “‘ICYP for 120min at 37” to determine 
total binding (TB). Unspecific binding (UB) was 
determined in parallel incubations with 1 /Imol/L 
unlabelled (-)timolol. Specific binding was defined 
as TB - UB. After the incubation period, the 
samples were centrifuged at 15,000 g for 5 min and 
the supernatant was removed by suction. The pellets 
were counted in a Packard Gamma Spectrometer 
(model 5360). 
Specific binding data were iteratively fitted by 
non-linear regression analysis to a model of two 
independent binding sites as described earlier 
[35,37], using the Enzfitter program from Biosoft@. 
Cambridge, U.K. This model was used because 
previous studies in our own laboratory, as well as in 
other laboratories, suggested the existence of two 
rather than one binding site for /$-adrenoceptors on 
human MNL [35,37,38]. Binding data were also 
plotted according to the method of Scatchard [39] 
in order to visualize results. Since the functional and 
molecular properties of the low affinity binding site 
are yet to be defined, only the results for the high 
affinity binding site were considered, and the high 
affinity binding site was called &adrenoceptor. Kn 
and B,,, represented the equilibrium dissociation 
constant and density of the high affinity binding site 
in the saturation experiments. 
Stimulation of AC andcAMP assay. MNL (5 X lo5 
in SOOpL) were preincubated for 30min at 20” in 
the presence of 10-3mol/L IBMX to inhibit 
phosphodiesterase activity. Thereafter, the cells 
were incubated at 37” with isoproterenol (0, 1O-x. 
5 X 10m7 and lo-” mol/L) for 10 min. cholera toxin 
(0,lOV and lo-” /mL) for 60 or 120 min, or 
forskolin (10m4 mol P L) for 15 min. Isoproterenol was 
diluted in HH buffer, cholera toxin in distilled water, 
and forskolin in 100% ethanol (control experiments 
with ethanol revealed no influence on cAMP 
accumulation). The reaction was stopped by 
incubating the ceils at 100” for 5 min. Thereafter, 
the cells were centrifuged at 15.000 g, 300 ILL of the 
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Fig. 1. (a) Binding curves and Scatchard plot of a satura- 
tion experiment with “‘ICYP and intact lymphocytes of 
a healthy male adult (78 years old). The binding parameters 
for the high affinity binding site obtained by non-linear 
regression analysis were: B,,,, = 455.8 sites/ceil, K,, = 
1.8 pmol/L. (b) Binding curves and Scatchard plot of a 
saturation experiment with ‘251CYP and intact lymphocytes 
of a female CLL patient, Binet stage A (75 years old). The 
binding parameters for the high affinity binding site 
obtained by non-linear regression analysis were: R,,_ = 
74.X sites/cell. Kd = 0.6 pmol/L. 
supernatant were removed and stored at -30”. until 
the CAMP content was determined in duplicate with 
a [‘*‘I]cAMP radioimmunoassay kit of Amersham 
Braunschweig, Germany (401. 
Statistics. Patients and controls were compared by 
the Mann-Whitney test for independent samples. 
A P value co.05 was regarded as statistically 
significant. All results are given as mean t SEM. 
RESULTS 
&Adrenoceptors in normal lymphocytes and lym- 
phoma cells 
Representative experiments of ““ICYP binding to 
intact MNL are shown in Fig. la and b. The 
number of high affinity “‘ICYP binding sites (&- 
adrenoceptors) per cell was 455.8 in MNL of a 74- 
year-old healthy person (Fig. la) and 74.8 in MNL 
of a 75-year-old CLL patient (Fig. lb). As a group 
phenomenon, the number of high affinity pZ- 
adrenergic binding sites per cell was approximately 
3-fold higher in normal lymphocytes (869.0 + 149.1) 
than in lymphoma cells (322.8 + 77.3; P < 0.01). 
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Fig. 2. Density (sites/cell = B,.J and equilibrium dissociation constant (I&) (means + SEM) of high 
affinity &adrenergic binding sites of human lymphoma cells (N = 15) and normal lymphocytes (N = 
7). * Difference from lymphoma: P < 0.01. 
The apparent affinity constant (&) exhibited no 
significant difference (Fig. 2). 
Stimulation of AC by different agents 
The basal CAMP accumulation of normal lym- 
phocytes and lymphoma cells showed no difference 
and did not significantly change within the incubation 
periods used (l&120 min). The intracellular CAMP 
accumulation after incubation with 10e4 mol/L 
isoproterenol was slightly lower in lymphoma cells 
(12.0 ? 2.0 pmol/lOh cells) as compared with normal 
lymphocytes (18.9 t 4.4 pmol/106 cells; P = 0.06). 
At lower concentrations of isoproterenol, the 
difference in CAMP accumulation between normal 
and malignant lymphocytes decreased. Cholera toxin 
increased the intracellular CAMP levels in normal 
and malignant lymphocytes to the same extent (for 
all concentrations and incubation periods used); 
these results, however, showed a considerable 
interindividual variation, particularly in lymphoma 
patients as demonstrated by large SEM ranges. 
Forskolin increased the intracellular CAMP accumu- 
lation of lymphoma cells to 22.3 t 3.3 pmol/106 cells 
(Fig. 3). In normal lymphocytes, this increase was 
about g-fold higher (163.3 -C 25.9 pmol/106 cells; 
P < 0.01). All results were checked for correlations 
with age of patients and controls without any 
significant result. 
DISCUSSION 
In agreement with previous investigations [ 18-201 
this study shows that the number of high affinity a- 
adrenergic binding sites is decreased in human low 
grade lymphoma cells as compared with normal 
lymphocytes (Figs. 1 and 2). The 3-fold lower density 
of &-adrenoceptors in malignant B-cells can neither 
be explained by age differences [41] nor by the 
elevated B-: T-cell ratio in lymphoma patients as 
compared with normal donors, because normal B- 
cells bear more /$,-adrenoceptors than T-cells 
[20,42,43]. The responsiveness of AC to iso- 
proterenol was only slightly decreased in MNL of 
lymphoma patients (Fig. 3). The function of the 
stimulating G protein, G,, seemed to be conserved 
in the malignant B-cells as demonstrated by the 
experiments with cholera toxin (Fig. 3). These results 
correspond well to similar experiments on CLL 
lymphocytes using NaF, another stimulator of G, 
[14, 181. Finally, the most relevant finding of this 
study was that the AC response to forskolin was 
considerably impaired in the malignant B-cells 
(Fig. 3). 
The results should be interpreted with caution 
because of the lack of investigations on the effect of 
forskolin in subpopulations of normal lymphocytes. 
However, the responsiveness of AC to a variety 
of compounds (isoproterenol, NaF, GTP and 
prostaglandin E,) was shown to be higher in B- 
lymphocytes than in T-lymphocytes [20]. Therefore, 
it does not seem probable that the decreased AC 
responsiveness to forskolin in malignant B-cells may 
be explained by the only difference of B- and T- 
cells. With these limitations in mind, it can be 
concluded from our experiments that the a- 
adrenergic signal transduction in malignant human 
B-cells seems to be impaired, above all at the AC 
level. Additionally, the density of &adrenoceptors 
is decreased. Both phenomena may account for 
decreased intracellular CAMP levels in these cells 
[17,20], thereby contributing to their malignant 
transformation [13, 17,22-281. 
In this context, Inhorn et al. [28] demonstrated 
that the restoration of the AC responsiveness to 
forskolin, cholera toxin and prostaglandin El by 
butyrate was responsible for the antiproliferative 
effects of these compounds in a murine myeloid cell 
line. The same authors provided evidence that an 
imbalance between the inhibitory G protein, Gi, and 
the stimulatory G protein, G,, might be responsible 
for the decreased AC activity of this cell line. 
Alterations of this balance and/or functional changes 
of Gi would also help to explain the impairment of 
the AC responsiveness to forskolin observed in this 
study in lymphoma cells. The AC might be 
permanently inhibited by an absolute or relative 
increase of the activity of Gi [44]. Other explanations 
include the permanent inhibition of AC by protein 
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Fig. 3. Stimulation of adenylate cyclase of human lymphoma cells (N = 15) and normal lymphocytes 
(N = 7) by different compounds (IS0 = isoproterenol, CHO = cholera toxin, FK = forksolin). For 
isoproterenol and cholera toxin, only two representative xperiments are shown, because experiments 
with different concentrations or incubation periods gave similar results. * Difference from lymphoma: 
P<O.Ol. 
kinase C known to be stimulated by different 
cytokines and (tumor) growth factors [45], mutations 
of AC at its catalytic or regulatory sites, a reduction 
of AC synthesis, or an increase of AC metabolism. 
However, increased inhibitory effects on AC, or 
changes of the catalytic subunit of AC do not explain 
by themselves that the stimulation of AC by 
isoproterenol and cholera toxin, though taking place 
upstream in the signal transduction pathway, seems 
to be less impaired than the direct AC stimulation 
with forskolin. One could expect that an impairment 
of AC should affect the signal transduction pathway 
to a similar extent at all levels upstream. Our 
experiments, however, showed no evidence that the 
AC impairment, as reflected by a significantly 
reduced responsiveness to forksolin, is necessarily 
paralleled by a similar decrease of its response to 
isoproterenol and cholera toxin in lymphoma cells. 
Therefore, a compensatory mechanism upstream of 
AC might balance the AC impairment to some 
extent. In our experiments, the &adrenoceptor 
number was decreased, and the receptor affinity was 
not changed in lymphoma cells. Therefore, an 
increase of the receptor density or affinity does not 
seem to compensate the AC impairment. The 
slightly, but not significantly increased CAMP 
accumulation in lymphoma cells in response to 
cholera toxin (Fig. 3) rather supports the hypothesis 
that the induction of more functional G, molecules 
could contribute to this compensation. However, 
this compensation seems to disappear with disease 
progression and increasing tumor cell proliferation, 
since the ability of cholera toxin to stimulate 
lymphocyte AC was found to decrease significantly 
with disease progression in CLL and IC patients 
(Hallek et al., unpublished data). 
The most satisfactory explanation derives from 
the comparison with cell line mutants defective in 
AC related signal transduction. Those cell lines, 
particularly S49 lymphoma mutants. proved to be 
powerful tools for studying the interaction between 
receptors, G proteins and AC [4&48]. Forksolin- 
resistant mutants of Yl adrenocortical tumor cells 
[49] share some common features with our findings 
in lymphoma cells, and therefore merit close 
comparison. These mutants had a decreased 
responsiveness of AC to forskolin. and, though to a 
lesser extent, to ACTH (via the receptor) and to 
Gpp(NH)p. a non-hydrolysable GTP analogue. On 
the contrary, AC was normally stimulated by 
NaF (via G,). Since the cholera toxin-mediated 
incorporation of [‘*PINAD to the N subunit of G, 
((u,) was reduced by 70%, a defect of a; was 
suggested. a; is the regulatory subunit of the G, 
heterotrimer that stimulates the catalytic unit of AC 
[44]. It seems to be required for the full stimulation 
of AC by forskolin, although forskolin is able to 
activate AC in the absence of functional active G, 
to some extent [47]. The observations on Y 1 mutants 
show similarities to the impairment of &adrenergic 
signal transduction reported in this study, where the 
CAMP accumulation was particularly decreased in 
response to forskolin, and to a lesser extent to 
isoproterenol (via the receptor) and cholera toxin 
(via G,) (Fig. 3). They provide a model in which the 
functionally active subunit of G,, cr,, rather than the 
catalytic unit of AC is altered. These alterations 
might account for the impairment of the /3-adrenergic 
signal transduction pathway in human B-cell 
lymphoma .
These findings await further investigations involv- 
ing the use of monoclonal antibodies against AC 
Reduced responsiveness of AC to forskolin 1333 
and subunits of G proteins for quantitation by 
Western blotting, the study of different transmem- 
brane signal pathways inhibiting AC, and the 
molecular analysis of the subunits of G, and AC in 
human lymphoma cells. Further studies of the p2- 
adrenergic signal transduction in lymphoma cells, 
with emphasis on the effects of forskolin, are under 
way. They may improve our understanding of the 
pathogenesis of lymphoma and help to develop new 
therapeutic strategies based on modifying the AC 
activity in lymphoma cells. 
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